A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to Rituximab Versus Lenalidomide in Addition to Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma Grade 1 to 3a or R/R Marginal Zone Lymphoma
- Patil, Sushrut (Primary Chief Investigator (PCI))
- Kennedy, Nola (Project Manager)
- Sungala, Nagendraprasad (Chief Investigator (CI))
- Cochrane, Tara (Chief Investigator (CI))
- Renwick, William (Chief Investigator (CI))
- Badoux, Xavier C. (Chief Investigator (CI))
- Chong, Geoffrey (Chief Investigator (CI))
- Leahy, Michael (Chief Investigator (CI))
- Lee, Denise (Chief Investigator (CI))
- Giri, Pratyush (Chief Investigator (CI))
- Presgrave, Peter (Chief Investigator (CI))
- Johnston, Anna M. (Chief Investigator (CI))
- Lee, Hui Peng (Chief Investigator (CI))
Project: Research